Rising Prevalence of Hemophilia, Increasing Adoption of Recombinant Therapies, and Breakthroughs in Gene Therapy Propel Market Growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Hemophilia Market Size & ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

In a volatile fourth quarter, the Wasatch Ultra Growth Fund—Investor Class returned 0.94% and slightly underperformed the benchmark Russell 2000® Growth Index, which rose 1.70%.

Jammu Hemophilia Society, in collaboration with the Department of Paediatrics of Shri Maharaja Gulab Singh (SMGS) Hospital ...

This pseudo-cleric averred that he could control the child’s illness. In fact, he did seem to have some marginal soothing ...

The global hemophilia treatment market is on a strong growth trajectory, with projections indicating a rise from USD 12.1 billion in 2024 to a remarkable USD 18.7 billion by 2034. This growth, driven ...

The Government of Kerala oversees the Kerala State Lotteries program. It was founded in 1967 and is the first of its kind in ...

Market Valuation Set to Surge from USD 13.23 Billion in 2024 at a CAGR of 5.69% ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Feb 20 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and ...